Once-weekly semaglutide in adolescents with obesity

Weghuber, Daniel, Barrett, Timothy, Barrientos-Pérez, Margarita, Gies, Inge, Hesse, Dan, Jeppesen, Ole K., Kelly, Aaron S., Mastrandrea, Lucy D. +2 more·2022·New England Journal of Medicine
DOI 10.1056/nejmoa2208601

Cited by (794)

Items 101–200 of 794

  1. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
    Goldenberg, Ronald M., Gilbert, Jeremy D., Manjoo, Priya, Pedersen, Sue D., Woo, Vincent C., Lovshin, Julie A. · 2024 · Obesity Reviews
  2. Semaglutide treatment for children with obesity: an observational study
    Elizabeth-Jane van Boxel, Saqib Rahman, Karen Lai, Nabil Boulos, Nikki L. Davis · 2024 · Archives of Disease in Childhood
  3. GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials
    Livia Miguel Romariz, Amanda Almeida Cavalcanti de Melo, Emma Ann Finnegan, Yasmin Luz Lima de Mesquita, Carolina Castro Porto Silva Janovsky · 2025 · Pediatric Research
  4. Recent advances in peptide-based therapies for obesity and type 2 diabetes
    Bailey, Clifford J., Flatt, Peter R., Conlon, J. Michael · 2024 · Peptides
  5. Intermittent Energy Restriction for Adolescents With Obesity
    Natalie B. Lister, Louise Alison Baur, Eve T. House, Shirley Alexander, Justin J. Brown, Clare Elizabeth Collins, Christopher T. C.T. Cowell, Kaitlin Day, Sarah P. Garnett, Megan L. Gow et al. · 2024 · Archives of Pediatrics and Adolescent Medicine
  6. Pediatric Obesity Pharmacotherapy: State of the Science, Research Gaps, and Opportunities
    Sarah Armstrong, Ihuoma Eneli, Stavroula K. Osganian, Brooke E. Wagner, Stephanie Waldrop, Aaron S. Kelly · 2024 · PEDIATRICS
  7. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
    Richard J. MacIsaac · 2025 · Future Cardiology
  8. Effect of drugs on nutritional status and drug–nutrition interactions in older patients
    Masafumi Kuzuya · 2023 · Geriatrics and gerontology international/Geriatrics & gerontology international
  9. Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood
    Stacey L. Simon, Phoutdavone Phimphasone‐Brady, Kathryn M. McKenney, Lauren D. Gulley, Andrea Elena Bonny, Jaime M. Moore, Carla Torres-Zegarra, Melanie Cree‐Green · 2024 · The Lancet Child & Adolescent Health
  10. Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond
    Emir M. Muzurović, Niki Katsiki, Špela Volčanšek, Fulvio Plescia, Manfredi Rizzo, Christos Socrates Mantzoros · 2026 · Metabolism
  11. Variation in responses to incretin therapy: Modifiable and non-modifiable factors
    Gregory O. Austin, Alejandra Tomás · 2023 · Frontiers in Molecular Biosciences
  12. Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
    Muhammad Aaqib Shamim, Amol Patil, Ulfat Amin, Tuli Roy, Krishna Tiwari, Noor Husain, Jogender Kumar, Santenna Chenchula, Priyanka Prasad Rao, Venkata Ganesh et al. · 2024 · Diabetes Obesity and Metabolism
  13. Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
    Karen Montecinos, Barbara Kania, David J. Goldberg · 2024 · Dermatological Reviews
  14. Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
    Ellen Jensen, Mads Egerod Israelsen, Aleksander Ahm Krag · 2024 · Hepatology Communications
  15. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
    Masson, Walter, Lobo, Martín, Barbagelata, Leandro, Lavalle-Cobo, Augusto, Nogueira, Juan P. · 2024 · Endocrinología, Diabetes y Nutrición (English ed.)
  16. Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis
    Luis Gustavo Sedenho‐Prado, Louise Buonalumi Tácito Yugar, Ana Raquel Whitaker, Mônica Martins, Daniel Campos Jesus, Isadora Maria Castilho da Silva Ferreira, Cleide Aparecida Moreira Silva, Wilson Nadruz, Cíntia Cercato, Andrei Carvalho Sposito · 2025 · International Journal of Obesity
  17. The ‘breakthrough’ obesity drugs that have stunned researchers
    McKenzie Prillaman · 2023 · Nature
  18. How can physical activity facilitate a sustainable future? Reducing obesity and chronic disease
    David J. Stensel · 2023 · Proceedings of The Nutrition Society
  19. Clinical review: Guide to pharmacological management in pediatric obesity medicine
    Valerie M. O’Hara, Suzanne E. Cuda, Roohi Y. Kharofa, Marisa Censani, Rushika Conroy, Nancy Tkacz Browne · 2023 · Obesity Pillars
  20. Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
    Casey Berman, Alaina P. Vidmar, Lily C. Chao · 2023 · touchREVIEWS in Endocrinology
  21. Kidney Considerations in Pediatric Obesity
    Alexandra Sawyer, Evan M. Zeitler, Howard Trachtman, Petter Bjornstad · 2023 · Current Obesity Reports
  22. Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics
    Jinliang Liang, Huanyi Liu, Guo Lv, Xiaotong Chen, Zhaoshou Yang, Kunhua Hu, Hongyan Sun · 2025 · Lipids in Health and Disease
  23. A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
    Yi Du, Mengting Zhang, Zhenjie Wang, Mengyi Hu, Dongxia Xie, Xiuzhu Wang, Zhuoming Guo, Jinfeng Zhu, Weichui Zhang, Ziyi Luo et al. · 2024 · Journal of Diabetes Investigation
  24. Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis
    Shuo Yang, Shuangqing Xin, Ronghui Ju, Peizhuo Zang · 2025 · PLoS ONE
  25. Debating Weight Loss vs. Weight Neutral Strategies for Improvements of Health
    Berit L. Heitmann, Rasmus Køster‐Rasmussen, Lene Bomholt Meyer, Sofus Christian Larsen, Fanney Þorsteinsdóttir, Catharina Thiel Sandholdt, Kirstine Nyvold Bojsen-Møller, Gritt Overbeck, Frans Boch Waldorff, Marius Brostrøm Kousgaard et al. · 2024 · Current Obesity Reports
  26. Obesity and Exercise: New Insights and Perspectives
    James, Natasha Maria, Stanford, Kristin I · 2025 · Endocrine Reviews
  27. Update in clinical science: MASLD in children and adolescents
    Sander Lefere, Bart G.P. Koot, Jake Peter Mann, Philip Bufler, Ruth De Bruyne, Christian A. Hudert · 2026 · Journal of Hepatology
  28. The Role of the Gut Microbiome in Pediatric Obesity and Bariatric Surgery
    Cynthia Akagbosu, Evan P. Nadler, Shira Levy, Suchitra K. Hourigan · 2022 · International Journal of Molecular Sciences
  29. Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
    Mark A. Moyad · 2023 · Current Urology Reports
  30. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management
    Ashwin K. Chetty, Ebne Rafi, Natalie J. Bellini, Natalie Buchholz, Diana M. Isaacs · 2023 · Endocrine Practice
  31. Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
    Merle L. Myerson, Rodis D. Paparodis · 2024 · The Journal of Clinical Pharmacology
  32. The role of incretin receptor agonists in the treatment of obesity
    Thomas M. Forst, Christophe E.M. De Block, Stefano Del Prato, Sara Armani, Juan P. Frías, Anne Lautenbach, Bernhard H. Ludvik, Marina Marinez, Chantal Mathieu, Timo D. Müller et al. · 2024 · Diabetes Obesity and Metabolism
  33. Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?
    Maria Kałas, Ewelina Stępniewska, Michał Gniedziejko, Jakub Leszczyński-Czeczatka, Mariusz Siemiński · 2025 · Journal of Clinical Medicine
  34. Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022
    Suzanne E. Cuda, Marisa Censani, Roohi Y. Kharofa, Valerie M. O’Hara, Rushika Conroy, Dominique R. Williams, Jennifer Paisley, Allen F. Browne, Sara Karjoo, Nancy Tkacz Browne · 2022 · Obesity Pillars
  35. Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
    Yilong Yan, Ying Gong, Meizhu Jiang, Yiming Gao, Shanshan Guo, Jiping Huo, Zhigang Zhao, Cao Li · 2023 · Frontiers in Endocrinology
  36. Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study
    Cristina Sciacovelli, Ginevra Moschione, Silvia Garelli, Uberto Pagotto · 2023 · JCEM Case Reports
  37. The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide
    Peter Kurtzhals, Frederik Flindt Kreiner, Rubdeep Singh Bindra · 2023 · Diabetes Research and Clinical Practice
  38. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
    Rasha Abi Radi Abou Jaoudeh, Phillipp Hartmann, Ole Olson, Olga T. Gupta, Seema Kumar, Samar H. Ibrahim, Rima L. Fawaz, Amal A. Aqul, Sara Mohammed Hassan · 2024 · Journal of Pediatric Gastroenterology and Nutrition
  39. Practice Recommendations for Metabolic Dysfunction–Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN)
    Vikrant Sood, Seema Alam, Aabha S. Nagral, Anshu Srivastava, Aniket Deshmukh, Ashish Bavdekar, Bhaswati Chakrabarti Acharyya, S. Geetha, Girish L. Gupte, Ishitaa Bhatia et al. · 2024 · Indian Pediatrics
  40. Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database
    Min Wang, Zhiyun Yang, Min Yan, Liu Shao, Sa Xiao · 2025 · Journal of Affective Disorders
  41. Call to action—Pediatric MASLD requires immediate attention to curb health crisis
    Phillipp Hartmann, Marialena Mouzaki, Sara Mohammed Hassan, Mohit Kehar, Krupa R. Mysore, Erin E. Mauney, Dieudonne Nonga, Sara Karjoo, Shilpa Sood, Andrea M. Tou et al. · 2025 · Hepatology
  42. Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
    Isabel Krug, An Binh Dang, Jade Portingale, Yakun Li, Ying Qing Won · 2025 · Nutrients
  43. A two-sample Mendelian randomization study of circulating lipids and deep venous thrombosis
    Pan Luo, Qiling Yuan, Xianjie Wan, Mingyi Yang, Peng Xu · 2023 · Scientific Reports
  44. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study
    Roger S. McIntyre, Angela T.H. Kwan · 2024 · Expert Opinion on Drug Safety
  45. Multi-faceted roles of β-arrestins in G protein-coupled receptor endocytosis
    Junke Liu, Xue Li, Magalie A. Ravier, Floriane Eshak, Francine Acher, Anne Goupil-Lamy, Marta Cimadevila, Julia Drube, Carsten Hoffmann, Asuka Inoue et al. · 2025 · Nature Communications
  46. A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity
    Anthony Kim, Jennifer Nguyen, Mahsa Babaei, Ahlee Kim, David H. Geller, Alaina P. Vidmar · 2023 · Adolescent Health Medicine and Therapeutics
  47. Weight Loss and Glycemic Control After Bariatric Surgery in Adolescents With Severe Obesity: A Randomized Controlled Trial
    Yvonne G. M. Roebroek, Givan Florian Paulus, Ali Talib, Edgar van Mil, Anita C. E. Vreugdenhil, Björn Winkens, Coen D.A. Stehouwer, Jan-Willem M. Greve, Nicole D. Bouvy, Ernst L.W. van Heurn · 2023 · Journal of Adolescent Health
  48. Management of obesity in menopause
    Santiago Palacios, Peter A. Chedraui, Rafael Sánchez‐Borrego, Pluvio Coronado, Tommaso Simoncini, Katrin Schauding, Tim Hillard, Rossella Elena Nappi · 2024 · Climacteric
  49. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice
    Megan O. Bensignor, Silva A Arslanian, Mary Ellen Vajravelu · 2024 · Current Opinion in Pediatrics
  50. Semaglutide and social media: implications for young women with polycystic ovarian syndrome
    Sabrina Keating, Cervantée E. K. Wild · 2023 · The Lancet Child & Adolescent Health
  51. Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management
    Mostafa Salama, Bridget K. Biggs, Ana L. Creo, Rose Prissel, Alaa Al Nofal, Seema Kumar · 2023 · Diabetes Metabolic Syndrome and Obesity
  52. Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Erika Choi, Ana Ramirez Tovar, Zhulin He, Dellys Soler Rodriguez, Miriam B. Vos, Shruthi Arora, Doris Fadoju · 2024 · Children
  53. Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review
    Elżbieta Niechciał, Paulina Wais, Jan Bajtek, Andrzej W. Kędzia · 2024 · Nutrients
  54. Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity
    Megan O. Bensignor, Aaron S. Kelly, Alicia Kunin‐Batson, Claudia K. Fox, REBECCA L. FREESE, Justin Clark, Kyle D. Rudser, Eric Morris Bomberg, Justin R. Ryder, Amy C. Gross · 2024 · Pediatric Obesity
  55. Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity
    Patil Kavarian, T E MOSHER, Marwa Abu El Haija · 2024 · Current Opinion in Pediatrics
  56. The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis
    Jian‐Ying Wang, Jyun‐Wei Kang, Chih‐Yuan Wu, Tzu‐Rong Peng, Ling‐Mei Liao, Ming‐Chia Lee, Jen‐Ai Lee, Shih‐Ming Chen · 2024 · Obesity Reviews
  57. Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity
    Mary Ellen Vajravelu, Patricia Y. Chu, David A. Frank, Maya I. Ragavan, Ravy K. Vajravelu · 2024 · Pediatric Obesity
  58. Assessing the state of obesity care: Quality, access, guidelines, and standards
    Lee M. Kaplan, Caroline Margaret Apovian, Jamy D. Ard, David B. Allison, Louis J. Aronne, Rachel Louise Batterham, Luca Busetto, Dror Dicker, Deborah Bade Horn, Aaron S. Kelly et al. · 2024 · Obesity Science & Practice
  59. Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta‐analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline
    Gita Wahi, Julie St‐Pierre, Bradley C. Johnston, Donna Fitzpatrick‐Lewis, Ali Usman, Diana Sherifali, Roah A. Merdad, Zahra Esmaeilinezhad, Catherine S. Birken, Jill K. Hamilton et al. · 2024 · Pediatric Obesity
  60. Exploring the antioxidant properties of semaglutide: A comprehensive review
    Habib Yaribeygi, Mina Maleki, Behina Forouzanmehr, Prashant Kesharwani, Tannaz Jamialahmadi, Sercan Karav, Amirhossein Sahebkar · 2024 · Journal of Diabetes and its Complications
  61. Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
    Thomas M. Forst, Christophe E.M. De Block, Stefano Del Prato, Juan P. Frías, Anne Lautenbach, Bernhard H. Ludvik, Marina Marinez, Chantal Mathieu, Timo D. Müller, Oliver Schnell · 2025 · Diabetes Obesity and Metabolism
  62. The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research
    Caroline J. Violette, Ravi Agarwal, Rachel S. Mandelbaum, José Luis González, Kurt M. Hong, Lynda D. Roman, Maximilan Klar, Jason Dennis Wright, Richard J. Paulson, Andreas Obermair et al. · 2023 · Expert Review of Anticancer Therapy
  63. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
    Hussein Zaitoon, Aimee D. Wauters, Luisa M. Rodríguez, Jane Lockwood Lynch · 2025 · Children
  64. iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025 - Focus on prevention and treatment of cardiometabolic disease
    Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J.S. Coats, Dike Ojji, Adriana Puente-Barragán, Peter R Rossing, Shelley R. Zieroth, Shaaf Ahmad, Shariq Usman et al. · 2025 · Global Cardiology
  65. Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment
    Kallirhoe Kalinderi, Vasiliki Goula, Evdoxia Sapountzi, Vasiliki Rengina Tsinopoulou, Liana Fidani · 2024 · Children
  66. Bone health following paediatric and adolescent bariatric surgery: a systematic review and meta-analysis
    Anuja T. Mitra, Bibek Das, Khaled Maher Sarraf, Martha Ford‐Adams, Matyas Fehervari, Hutan Ashrafian · 2024 · EClinicalMedicine
  67. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
    Walter M. Masson, Martín Lobo, Leandro Barbagelata, Augusto Lavalle Cobo, Juan Patricio Nogueira · 2024 · Endocrinología Diabetes y Nutrición
  68. Obesity treatment in adolescents and adults in the era of personalized medicine
    Magnus Sundbom, Kajsa Järvholm, Lovisa Sjögren, Paulina Nowicka, Ylva Trolle Lagerros · 2024 · Journal of Internal Medicine
  69. Metabolic outcomes of bariatric surgery versus lifestyle intervention in adolescents with severe obesity: A systematic review and meta‐analysis
    Abul B. M. Kamrul-Hasan, Joseph M Pappachan, Lakshmi Nagendra, Hamid Ashraf, Deep Dutta, Saptarshi Bhattacharya, Nitin Kapoor · 2025 · Clinical Obesity
  70. Obesity phenotypes and atherogenic dyslipidemias
    Hun Jee Choe, Talal Almas, Ian J. Neeland, Soo Kyung Lim, Jean‐Pierre Després · 2025 · European Journal of Clinical Investigation
  71. Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study
    Kathrine Vauvert Römmelmayer Hviid, Karina Banasik, Laust Hvas Mortensen, Sten Madsbad, Katrine Strandberg‐Larsen, Nina Rica Wium Geiker, David Westergaard, Henriette Svarre Nielsen · 2026 · Human Reproduction Open
  72. Who benefits most from outpatient lifestyle intervention? An IMI‐SOPHIA study on pediatric individuals living with overweight and obesity
    Nicole Prinz, Hugo Pomares‐Millan, Almut Dannemann, Giuseppe Nicola Giordano, Christine Joisten, Antje Körner, Daniel Weghuber, Susann Blüher, Susanna Wiegand, Reinhard Walter Holl et al. · 2023 · Obesity
  73. Cardio‐renal‐metabolic disease in primary care setting
    Mahmoud Ashraf Ibrahim, Ebtesam M. Ba-Essa, Jason C. Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie Jane Davies, Robert H. Eckel, Luc Van Gaal, Peter Gæde et al. · 2023 · Diabetes/Metabolism Research and Reviews
  74. Primary care perspectives on prescribing anti‐obesity medication for adolescents
    Rutha Chivate, Pamela L. Schoemer, Maya I. Ragavan, Kristin N. Ray, Megan O. Bensignor, Andrea Beth Goldschmidt, Mary Ellen Vajravelu · 2024 · Pediatric Obesity
  75. Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target
    Shiying Lei, Jiajun Sun, Yifang Xie, Xiaojuan Xiao, Xiao‐Feng He, Sheng Lin, Huifang Zhang, Zineng Huang, Haiqin Wang, Xusheng Wu et al. · 2024 · Carcinogenesis
  76. Beyond weight loss: exploring the neurological ramifications of altered gut microbiota post-bariatric surgery
    Rashed T. Almheiri, Baraa Mohammed Hajjar, Saif M I Alkhaaldi, Nadia Rabeh, Sara Aljoudi, Khaled S. Abd‐Elrahman, Hamdan Hamdan · 2025 · Journal of Translational Medicine
  77. What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
    Allan I Pack, Ronald R. Grunstein, Babak Mokhlesi, Silke Ryan, R Schwab, David Gozal · 2025 · SLEEP
  78. Glucagon-like peptide-1: a new potential regulator for mesenchymal stem cells in the treatment of type 2 diabetes mellitus and its complication
    Zi’an Shao, Xiaoguang Zhang, Junrong Cai, Feng Lu · 2025 · Stem Cell Research & Therapy
  79. An update on multimodal management of craniopharyngioma in children
    Laura‐Nanna Lohkamp, Ekkehard Matthias Kasper, Alexandra Espinosa Pousa, Ute Katharina Bartels · 2023 · Frontiers in Oncology
  80. Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
    Evgenia Koureta, Εvangelos Cholongitas · 2024 · Frontiers in Pharmacology
  81. Pediatric MASLD in China: epidemiology, screening, diagnosis, and management
    Xiaoguo Li, Xiaodong Zhou, Jie Wu, Zhenhua Zhao, Feng Xie, Yiling Li, Wenhui Li, Xiaosong Yan, Sumin Sui, Liting Zhang et al. · 2025 · The Lancet Regional Health - Western Pacific
  82. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials
    Min Dai, Senjie Dai, Lihu Gu, Zhiyi Xiang, Anyi Xu, Siyu Lu, Yang Yang, Cong Zhou · 2024 · Journal of Clinical Research in Pediatric Endocrinology
  83. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Nilesh T Katole, Harsh V Salankar, Ajay Manikrao Khade, Jyoti S Kale, Nandkishor Jageshwar Bankar, Punam A. Gosavi, Bhushan Dudhe, Nishikant Mankar, Obaid Noman · 2024 · Cureus
  84. Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives
    Dániel Horváth, Pál Stráner, Nóra Taricska, Zsolt Fazekas, Dóra K. Menyhárd, András Perczel · 2024 · Journal of Medicinal Chemistry
  85. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression
    Moein Ala, Mohammadreza Moheb Aleaba · 2024 · Journal of Endocrinological Investigation
  86. Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
    Georgios S. Papaetis, Michalis K. Picolos, Anastasia Sacharidou · 2025 · Archives of Medical Science - Atherosclerotic Diseases
  87. Prolonged Semaglutide Treatment Reveals Stage-Dependent Changes to Feeding Behavior and Metabolic Adaptations in Male Mice
    Harsh Shah, Julio E. Ayala · 2025 · Diabetes
  88. Novel therapeutics in rare genetic obesities: A narrative review
    Béatrice Dubern, Nathan Faccioli, Christine Poitou, Karine Clément · 2023 · Pharmacological Research
  89. Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
    Rasmus Stenlid, Sara Y. Cerenius, Wen Quan, Banu Küçükemre Aydın, Hannes Manell, Azazul Islam Chowdhury, Hjalti Kristinsson, Iris Ciba, Erik S. Gjessing, Katharina Mörwald et al. · 2023 · Frontiers in Endocrinology
  90. Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies
    Francesca Mainieri, Saverio La Bella, Marta Rinaldi, Francesco Chiarelli · 2024 · European Journal of Pediatrics
  91. Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
    Yoon Ji Ahn, Jacqueline Maya, Vibha Singhal · 2024 · Current Obesity Reports
  92. Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024
    Suzanne E. Cuda, Marisa Censani, Valerie M. O’Hara, Jennifer Paisley, Roohi Y. Kharofa, Rushika Conroy, Brooke R. Sweeney, Cristina Fernández, Meredith L. Dreyer Gillette, Nancy Tkacz Browne · 2024 · Obesity Pillars
  93. Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis
    Zhang, Shaolong, Yu, Boran, Xu, Jiamin, Jin, Siyao, Li, Yanming, Bing, Hao, Li, Jueyu, Ma, Xiangyu, Zhang, Xianhua, Zhao, Libo · 2025 · Diabetes Technology & Therapeutics
  94. Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report
    Pon Ramya Gokul, Louise Jayne Apperley, Jennifer Parkinson, Kate Clark, Kim Lund, Megan Owens, Senthil Senniappan · 2024 · Hormone Research in Paediatrics
  95. Compared to dual-energy X-ray absorptiometry, bioelectrical impedance effectively monitors longitudinal changes in body composition in children and adolescents with obesity during a lifestyle intervention
    Camilla Raaby Benjaminsen, Rasmus Møller Jørgensen, Esben Thyssen Vestergaard, Jens Meldgaard Bruun · 2024 · Nutrition Research
  96. Antiobesity medications in adult and pediatric obesity and metabolic dysfunction–associated steatotic liver disease
    Natalie S. Rodriguez, Phillipp Hartmann · 2025 · Pharmacological Reviews
  97. GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
    Hiba Jebeile, Yngvild Sørebø Danielsen, Priya Sumithran, Sasha J. Lorien, Isabelle R. Jardine, Louise Alison Baur, Natalie B. Lister · 2025 · Obesity Reviews
  98. Estimating the effects of preventive and weight-management interventions on the prevalence of childhood obesity in England: a modelling study
    Simon Russell, Oliver Tristan Mytton, Russell Viner · 2023 · The Lancet Public Health
  99. Multidisciplinary combined treatment based on bariatric surgery for metabolic syndrome: a review article
    Jiaji Xie, Yong Wang · 2024 · International Journal of Surgery
  100. Genetics, pharmacotherapy, and dietary interventions in childhood obesity
    Joe Eun Son · 2024 · Journal of Pharmacy & Pharmaceutical Sciences